This week in Drug Discovery (19 – 23 January)
News round-up for 19 – 23 January by Bruno Quinney, Content Team at DDW.
This week in DDW, innovative therapies have shown encouraging results in tackling melanoma and concussion. Elsewhere, a UK-Canadian partnership looks to advance vaccine technology.
The top stories:
Combination therapy could slash melanoma mortality risk
An investigational mRNA-based individualised neoantigen therapy (INT) reduced the risk of high-risk melanoma recurrence or death by 49% when combined with Keytruda (pembrolizumab).
Read more…
Oxeia advances potential first FDA-approved concussion drug
OXE103, a therapy for persistent concussion symptoms, demonstrated an 85% responder rate in Phase IIa clinical testing and will be evaluated in a Phase IIb trial.
UK-Canadian partnership to advance vaccine technology
A £750,000 ($1 million) global collaboration has been launched to advance next-generation vaccine technology.
104 new drugs approved in Europe in 2025
In 2025, the European Medicines Agency (EMA) recommended 104 medicines for marketing authorisation, 38 of which had a new active substance which had never been authorised in the European Union (EU) before.
ELRIG announces keynote speakers for CGT conference
ELRIG has announced Dr Stephen Ward and Dr Annarita Miccio as keynote speakers for its Cell and Gene Therapy event in March.